Wednesday, 15 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 15 January 2025
News

MSD drops $16b into IBD fight

Posted 18 April 2023 AM

MSD is making a $16 billion bid to boost its autoimmune pipeline with a promising candidate for ulcerative colitis and Crohn's disease, making an offer for NASDAQ-listed Prometheus Biosciences.

The main target is the TL1A inhibitor, PRA023. Prometheus announced extremely promising results from Phase 2 studies last year, which targeted moderate to severely active ulcerative colitis and moderate to severe Crohn's disease. It is also in Phase 2 trials for systemic scleroderma interstitial lung disease.

To see the whole article, please login

Popular

Pharmas ready to file new drugs
Four PBS listings kick off 2025
Guess who's scored a new job?
Govt skirts 'contempt' for pharma
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home